Flow cytometric analysis of human PBMC (human peripheral blood mononuclear cell) labelling CD19 antibody at 1/2000 (0.1 μg) dilution (Right) compared with a Mouse monoclonal IgG isotype control (Left). Goat Anti - Mouse IgG Alexa Fluor® 488 was used as the secondary antibody. Then cells were stained with CD3 - Brilliant Violet 421™ separately. Gated on total viable cells.
Product Details
Product Details
Product Specification
Host | Mouse |
Antigen | CD19 |
Synonyms | B-lymphocyte antigen CD19, LE-CD19, B-lymphocyte surface antigen B4, Differentiation antigen CD19, T-cell surface antigen Leu-12 |
Location | Cell membrane |
Accession | P15391 |
Clone Number | S-R503-1 |
Antibody Type | Mouse mAb |
Isotype | IgG1 |
Application | FCM |
Reactivity | Hu |
Purification | Protein G |
Concentration | 2 mg/ml |
Conjugation | Unconjugated |
Physical Appearance | Liquid |
Storage Buffer | PBS, 40% Glycerol, 0.05% BSA, 0.03% Proclin 300 |
Stability & Storage | 12 months from date of receipt / reconstitution, -20 °C as supplied. |
Dilution
application | dilution | species |
FCM | 1:2000 |
Background
CD19 is a transmembrane glycoprotein and a member of the immunoglobulin superfamily, predominantly expressed on B lymphocytes, making it a significant marker for B cell development and function. It plays a crucial role in B cell activation, signal transduction, and growth regulation. CD19 is involved in the B cell receptor (BCR) signaling pathway, enhancing B cell activation thresholds and proliferation. In the context of disease, CD19 is highly expressed in most B cell malignancies, including acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), and B cell lymphomas, making it a promising target for immunotherapy. The CD19 molecule is also implicated in autoimmune and immunodeficiency disorders, with mutations in CD19 associated with severe immunodeficiency syndromes characterized by reduced antibody production.
Picture
Picture
FC
